Do you want to read an article? Please log in or register.
Glucagon-Like Peptide (GLP-1) Receptor Agonists in Inflammatory Bowel Disease: Mechanisms, Clinical Implications, and Therapeutic Potential
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis
J Crohns Colitis
Bayoumy AB, Clarke LM, Deepak P, Desai A, Sehgal P, Gorelik Y, Bar-Yoseph H, Villumsen M, Mulder CJJ, Stenvers DJ, Tushuizen ME, de Boer NKH
doi: 10.1093/ecco-jcc/jjaf181
Inflammatory Bowel Disease
Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Inflamm Bowel Dis
Desai A, Habib H, Khataniar H, Farraye FA, Sehgal P, Barnes EL, Kochhar GS, Hashash JG
doi: 10.1093/ibd/izaf301
Further Publications
Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials
BMC Gastroenterol
Tamilwanan S, Aziz Z, Rong LY, Bitar AN, Zarzour RHA, Alshehade SA
doi: 10.1186/s12876-025-04358-0
Inflammatory Bowel Disease
Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and Risk
J Crohns Colitis
Honap S, Debouverie M, Filippi M, Selchen D, Jairath V, Danese S, Peyrin-Biroulet L
doi: 10.1093/ecco-jcc/jjaf215
Inflammatory Bowel DiseaseFurther Publications
Bowel Urgency Improvement Correlates With Clinical, Biochemical, and Intestinal Ultrasound Improvements in Inflammatory Bowel Disease: A Cross Sectional Multicenter Study
United European Gastroenterol J
D'Amico F, Nardone OM, Bruno A, Allocca M, Zilli A, Furfaro F, Parigi TL, Solitano V, Ungaro F, Faggiani I, La Mantia A, Calabrese G, Fiorino G, Jairath V, Peyrin-Biroulet L, Massimino L, Castiglione F, Danese S
doi: 10.1002/ueg2.70129
Inflammatory Bowel Disease
Clinical Research: Disparities in Outcomes for Patients With Inflammatory Bowel Disease at a Private vs Public Hospital in New York City
Inflamm Bowel Dis
Klein S, Sivasailam B, Alizadeh M, Malter L, Axelrad JE
doi: 10.1093/ibd/izaf174
Inflammatory Bowel Disease
Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice
Inflamm Bowel Dis
Gisbert JP, Chaparro M
doi: 10.1093/ibd/izaf273
COMMENTED
Inflammatory Bowel DiseaseFurther Publications
A Prospective Interventional Study to Evaluate the Effect of Hypoxia on Healthy Volunteers and Patients With Inflammatory Bowel Disease: The Altitude Inflammatory Bowel Disease Study
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Am J Gastroenterol
Vavricka SR, Zeitz J, Madanchi M, Ruiz PA, Biedermann L, Morsy Y, Yilmaz B, Scharl M, Scharl S, Gassmann M, Lutz TA, Kunz A, Bron D, Misselwitz B, MacPherson AJ, Rogler G, Greuter T
doi: 10.14309/ajg.0000000000003888
Inflammatory Bowel Disease
Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource
Inflamm Bowel Dis
Yan K, Vuyyuru SK, Taylor A, Figueredo G, Raine T, Sanon M, Naessens D, Munje C, Moran GW
doi: 10.1093/ibd/izaf276